Medicare Alzheimer's Drug Spending Falls Short of Projections by Billions

References

1. 1.Herman, B. (2026). Medicare is spending far less than expected on new Alzheimer's drugs. STAT News. https://www.statnews.com/2026/05/11/medicare-spending-less-than-expected-alzheimers-drugs-leqembi-kisunla/
2. 2.Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2024). Aducanumab produced a clinically meaningful benefit in patients with early Alzheimer's disease. Alzheimer's & Dementia, 20(2), 1346-1359. https://doi.org/10.1002/alz.12845
3. 3.Alexander, G. C., Emerson, S., & Kesselheim, A. S. (2024). Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA, 331(4), 330-338. https://doi.org/10.1001/jama.2024.2321
4. 4.Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., ... & Mintun, M. A. (2023). Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512-527. https://doi.org/10.1001/jama.2023.13239
5. 5.Rabinovici, G. D. (2024). Controversy and progress in Alzheimer's disease - FDA approval of aducanumab. New England Journal of Medicine, 390(9), 771-774. https://doi.org/10.1056/NEJMp2114501
6. 6.Honig, L. S., Barakos, J., Dhadda, S., Kanekiyo, M., Reyderman, L., Irizarry, M., ... & Kramer, L. D. (2023). ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 9(2), e12318. https://doi.org/10.1002/trc2.12318
7. 7.Knopman, D. S., Jones, D. T., & Greicius, M. D. (2024). Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen. Alzheimer's & Dementia, 20(3), 1777-1790. https://doi.org/10.1002/alz.12213
8. 8.Mahase, E. (2024). Alzheimer's drug lecanemab: European regulator cites safety concerns in rejection. BMJ, 386, q1456. https://doi.org/10.1136/bmj.q1456
9. 9.Walsh, S., Merrick, R., Milne, R., & Brayne, C. (2024). Aducanumab for Alzheimer's disease? A systematic review of clinical, cost-effectiveness and ethical considerations. European Journal of Neurology, 31(4), e15707. https://doi.org/10.1111/ene.15707